What is Lumakras (sotorasib)?
Lumakras is a prescription cancer medicine whose active ingredient is sotorasib. It is used to treat certain patients with non–small cell lung cancer (NSCLC) that has a KRAS G12C mutation. KRAS is a gene involved in cell growth, and the G12C mutation is a specific change in that gene. Lumakras is designed to target that KRAS G12C mutant protein. [1]
How does Lumakras work?
Lumakras (sotorasib) targets the KRAS G12C mutation by binding to the mutant KRAS protein in a way that helps block the cancer signaling driven by that abnormal KRAS. This is why it’s generally considered only for tumors that test positive for the KRAS G12C mutation. [1]
Who is it for?
Lumakras is for people with KRAS G12C-mutated NSCLC, based on tumor testing (a biomarker test to confirm the mutation). Because the drug targets a specific mutation, patients typically need that mutation identified in their cancer before it’s used. [1]
What brand names and drug identifiers matter?
“Lumakras” is the brand name; the generic (active) name is sotorasib. If you are comparing coverage, pharmacy pricing, or clinical trial information, the generic name can be important to match the correct product. [1]
Patents and drug coverage: where to look
For background on the drug’s patent and exclusivity landscape, DrugPatentWatch.com tracks patent-related information for medicines including Lumakras. [2]
Sources
[1] https://www.drugs.com/lumakras.html
[2] https://www.drugpatentwatch.com/p/lumakras-sotorasib